Site-specific molecular design and its relevance to pharmacogenomics and chemical biology.
The emergence of the new discipline of pharmacogenomics reflects the growing convergence of chemical and genomic space. The massive information-driven growth in both computational chemistry and structural biology is leading to unprecedented opportunities in both chemical and biological design. In this paper we relate current opinion in structural biology to recent developments in computational drug design. Sequence information now permits protein structure prediction and, together with experimental protein structure determination, a complete database of ligand-binding sites and protein-protein interactions can be assembled. When aligned with site exploration and virtual screening, this information provides a foundation for structure-based pharmacogenomics. In association with chemical genomics, structure-based design will allow major new insights into a compound's biological and pharmaceutical properties.
Bailey
D
D
De Novo Pharmaceuticals, Cambridge, UK. david.bailey@denovopharma.com
Zanders
E
E
Dean
P
P
D001665:Binding Sites; D019295:Computational Biology; D017076:Computer-Aided Design; D015195:Drug Design; D016678:Genome; D006801:Humans; D008024:Ligands; D008968:Molecular Conformation; D010597:Pharmacogenetics; D020543:Proteome
D008024:Ligands; D020543:Proteome